Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria : Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT) - 06/08/11
, Folkert W. Asselbergs, MD, PhD a, b, Hans L. Hillege, MD, PhD a, c, Rudolf A. de Boer, MD, PhD a, Ron T. Gansevoort, MD, PhD d, Dirk J. van Veldhuisen, MD, PhD a, Wiek H. van Gilst, PhD aRésumé |
Background |
The PREVEND IT investigated whether treatment targeted at lowering urinary albumin excretion (UAE) would reduce adverse cardiovascular events. We obtained extended follow-up data to approximately 10 years to investigate the long-term effects of fosinopril 20 mg and pravastatin 40 mg on cardiovascular outcomes in subjects with UAE >15 mg per 24 hours.
Methods |
The original PREVEND IT consisted of 864 participants and 839 survivors after 4 years. For every survivor, the primary end point determined by the combined incidence of cardiovascular mortality and hospitalization for cardiovascular morbidity was registered in several national databases and electronic hospital systems.
Results |
Mean total follow-up of the extended PREVEND IT was 9.5 years (range 9.4-10.7 years). Four years of treatment with fosinopril was not associated with a reduction in the primary end point compared with placebo (hazard ratio 0.87, 95% CI 0.61-1.24 [P = .42]) during long-term follow-up. After 9.5 years, subjects with a baseline UAE in the upper quintile (>50 mg/24 hours) had a total event rate of 29.5% and were at a higher risk for developing cardiovascular disease compared with less UAE (hazard ratio 2.03, 95% CI 1.38-2.97 [P ≤ .01]). In addition, 4 years of fosinopril treatment resulted in a risk reduction of 45% (95% CI 6%-75% [P = .04]) in this group compared with placebo. Subjects originally assigned to pravastatin had no overall risk reduction in the primary end point (P = .99).
Conclusions |
Elevated UAE is associated with increased cardiovascular mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk if the UAE is >50 mg per 24 hours. In this group, the benefits of 4-year treatment with fosinopril were sustained during posttrial follow-up for cardiovascular mortality and morbidity. We propose that UAE be used to estimate risk in the general population and that large clinical trials be designed to confirm the hypothesis that angiotensin-converting enzyme–inhibitor treatment may be beneficial in patients with mildly elevated UAE despite the absence of other comorbidities.
Le texte complet de cet article est disponible en PDF.Plan
Vol 161 - N° 6
P. 1171-1178 - juin 2011 Retour au numéro
Article précédent
- Interleukin 33 and ST2 in non–ST-elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP
- Onkar S. Dhillon, Hafid K. Narayan, Paulene A. Quinn, Iain B. Squire, Joan E. Davies, Leong L. Ng
- A multinational study of the influence of health-related quality of life on in-hospital outcome after coronary artery bypass graft surgery
- Andrea Székely, Nancy A. Nussmeier, Yinghui Miao, Kun Huang, Jack Levin, Helena Feierfeil, Dennis T. Mangano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?